Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/15/2017 11/16/2017 11/17/2017 11/20/2017 11/21/2017 Date
1.41(c) 1.56(c) 1.49(c) 1.46(c) 1.47 Last
366 728 407 807 309 979 183 649 11 061 Volume
-1.40% +10.64% -4.49% -2.01% +0.68% Change
More quotes
Financials ($)
Sales 2018 -
EBIT 2018 -33,8 M
Net income 2018 -33,9 M
Debt 2018 9,17 M
Yield 2018 -
Sales 2019 4,35 M
EBIT 2019 -36,1 M
Net income 2019 -35,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 36,3x
Capitalization 158 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development.It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.The company focuses on cell therapies for... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
11/14 Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlight..
11/08 PLURISTEM THERAPEUTICS : reports 1Q loss
11/07 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
11/07 PLURISTEM THERAPEUTICS : Enters into Agreement with Tel Aviv Sourasky Medical Ce..
11/06 Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Cond..
10/30 Pluristem Announces Pricing of Public Offering of Common Stock on the Tel Avi..
10/30 PLURISTEM THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (fo..
10/29 PLURISTEM THERAPEUTICS : Proposes to launch a public offering of common stock on..
10/26 Following Approval of Israel’s Ministry of Health, Pluristem Extends it..
10/23 Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic System..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/14 Pluristem Therapeutics reports Q1 results
10/30 Midday Gainers / Losers
10/30 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
10/30 PREMARKET LOSERS AS OF 9 : 05 am
10/30 Pluristem launches equity offering, shares down 14% premarket
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Technical analysis trends PLURISTEM THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,83 $
Spread / Average Target 163%
EPS Revisions
Managers
NameTitle
Zami Aberman Chairman & Co-Chief Executive Officer
Yaky Yanay President, Co-Chief Executive Officer & Director
Sagi Moran Vice President-Operations
Erez Egozi Chief Financial Officer, Secretary & Treasurer
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS INC.4.20%158
CELLTRION, INC.--.--%24 243
IQVIA HOLDINGS INC37.36%21 955
INCYTE CORPORATION5.19%20 882
LONZA GROUP59.15%19 698
ALNYLAM PHARMACEUTICALS, INC.240.57%12 601